Kelly M Mckenna

US Patent:

20170210803, Jul 27, 2017

Filed:

Jan 20, 2017

Appl. No.:

15/411623

Inventors:

- Stanford CA, US
Doris Po Yi Ho - Daly City CA, US
Kelly Marie McKenna - Palo Alto CA, US
Irving L. Weissman - Stanford CA, US
Jens-Peter Volkmer - Menlo Park CA, US
Mark P. Chao - Mountain View CA, US
Ravindra Majeti - Palo Alto CA, US
Melissa N. McCracken - Mountain View CA, US

International Classification:

C07K 16/28
A61K 45/06
A61K 39/395

Abstract:

Methods are provided for targeting cells for depletion, including without limitation cancer cells, in a regimen comprising contacting the targeted cells with a combination of immunoregulatory agents. The level of depletion of the targeted cell is enhanced relative to a regimen in which a single agent is used; and the effect may be synergistic relative to a regimen in which a single agent is used.

US Patent:

20170166645, Jun 15, 2017

Filed:

Dec 8, 2016

Appl. No.:

15/373150

Inventors:

- Stanford CA, US
Stephen Willingham - Sunnyvale CA, US
Doris Po Yi Ho - Stanford CA, US
Piero D. Dalerba - New York NY, US
Kelly Marie McKenna - Palo Alto CA, US
Jens-Peter Volkmer - Menlo Park CA, US

International Classification:

C07K 16/28

Abstract:

Methods are provided for targeting cells for depletion, including without limitation cancer cells, in a regimen comprising contacting the targeted cells with a combination of agents, including (i) an agent that blockades CD47 activity; and (ii) an antibody that specifically binds to EGFR. In some embodiments the cancer cells have a mutated form of one or more of KRAS, NRAS or BRAF. The level of depletion of the targeted cell is enhanced relative to a regimen in which a single agent is used; and the effect may be synergistic relative to a regimen in which a single agent is used.